Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $20.1 million.

  • Ani Pharmaceuticals' Shares Outstanding (Weighted Average) rose 345.29% to $20.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.1 million, marking a year-over-year increase of 345.29%. This contributed to the annual value of $19.3 million for FY2024, which is 731.63% up from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Shares Outstanding (Weighted Average) is $20.1 million, which was up 345.29% from $19.8 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Shares Outstanding (Weighted Average) ranged from a high of $20.1 million in Q3 2025 and a low of $12.0 million during Q1 2021
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $17.7 million (2023), whereas its average is $16.9 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first surged by 85.7% in 2021, then surged by 3465.76% in 2022.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $12.6 million in 2021, then rose by 29.09% to $16.3 million in 2022, then increased by 10.71% to $18.0 million in 2023, then rose by 7.32% to $19.3 million in 2024, then rose by 3.91% to $20.1 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $20.1 million in Q3 2025, compared to $19.8 million in Q2 2025 and $19.6 million in Q1 2025.